

# HELIX LOOP

Your inside track on Helix BioPharma – June 2026

Welcome back to The Helix Loop, Helix BioPharma's quarterly update on the people, progress, and priorities driving the Company forward.




After a brief pause since our last edition in the third quarter of 2025, we are pleased to return with the fourth issue of The Helix Loop, now moving from a bi-monthly to a quarterly format to provide a more focused and strategic view of our progress.

The past several months have been a defining period for Helix. While an anticipated financing transaction ultimately did not proceed, the experience sharpened our focus and reinforced our commitment to building a stronger, more resilient company. Since then, we have secured the capital required to support our near-term objectives, strengthened our leadership and governance functions, accelerated our pathway toward a planned Nasdaq uplisting, and completed the LDOS007 clinical protocol for our planned Phase IB/Randomized Phase II study in non-small cell lung cancer.

As we approach the second half of 2026, the Company is entering a new phase of growth with renewed momentum, a strengthened financial foundation, and a clear objective: execute on the Company's positioning for broader participation in the U.S. capital markets and advance L-DOS47 into its next stage of clinical development.

Thank you for continuing to follow our journey. Every advancement reinforces our commitment to **delivering innovative, clinically meaningful solutions** for people battling hard-to-treat cancers.

**Inside this issue:**

-  Financial and Corporate updates
-  Pipeline highlights
-  Traction

## Financial and Corporate Updates

- During late 2025, Helix entered into a fully executed and Toronto Stock Exchange-approved subscription agreement for a significant private placement financing. While the transaction ultimately did not proceed to funding due to circumstances affecting the investor, the experience reinforced the importance of maintaining multiple financing pathways and disciplined capital markets execution. Since then, Helix has advanced its financing strategy, strengthened its balance sheet, and continued progressing toward its planned Nasdaq uplisting and next clinical milestone for L-DOS47.
- On January 30, 2026, Helix held its Annual General and Special Meeting of Shareholders. A total of 61,885,815 shares were voted at the meeting, representing 81.03% of the Company's issued and outstanding shares. All motions were approved with over 99% shareholder approval.
- We have also strengthened our finance function, with Rohit Babbar, CPA, CA, Helix's Chief Financial Officer, now working with the Company on a full-time basis. This increased commitment adds dedicated and operational capacity as Helix advances its capital markets strategy and preparations for the next clinical milestone for L-DOS47.
- On June 3, 2026, Helix announced the closure of a non-brokered private placement of convertible debentures for aggregate proceeds of \$3.673 million, securing approximately 12 months of operating runway. This financing provides the Company with the stability required to advance its Nasdaq readiness initiatives, strengthen its capital markets positioning, and prepare for the next stage of development for L-DOS47. In parallel, an audit process is underway to support MJDS eligibility, alongside preparation of a base shelf prospectus to support the Company's future capital markets activities.
- On December 15, 2025, we released our interim financial results as of and for the three-month period ended October 31, 2025.
- Helix has been working to pave the way for a planned listing on Nasdaq via the Multijurisdictional Disclosure System (MJDS). On May 13, 2026, we announced the appointments of Zachary T. Stadnyk to the Board of Directors and Natalia L. Butterworth as Corporate Secretary, adding capital markets, biotech financing, and corporate governance expertise as the Company advances its financing strategy and planned uplisting pathway. In connection with these initiatives, Helix announced the relocation of its registered and records office from Toronto, Ontario to Vancouver, British Columbia, aligning its corporate infrastructure with its capital markets strategy.
- On March 16, 2026, we released our interim financial results as of and for the three- and six-month periods ended January 31, 2026. Following the end of the reporting period, the Company signed a term sheet with Alumni Capital Limited in respect of a potential financing transaction. While the specific commercial terms remain confidential, the term sheet reflects our continued focus on securing the financing needed to support Helix's next phase of growth.
- Helix continues to actively advance preparations for a planned Nasdaq uplisting through the MJDS pathway. Key milestones completed to date include strengthening of the Board and governance structure, enhancing financial leadership, securing operating runway, audit activities, and preparing a base shelf prospectus. The Company anticipates execution on its Nasdaq uplisting during the second half of 2026, subject to market conditions and regulatory approvals.

## Pipeline Highlights



### L-DOS47 Phase IB in NSCLC:


Following constructive End-of-Phase I discussions with the FDA in August 2025 and the completion of the LDOS007 protocol, Helix is approaching an important inflection point for L-DOS47. The planned Phase IB/Randomized Phase 2 study in non-small cell lung cancer (NSCLC) is designed not only to identify the optimal biological dose of L-DOS47 through advanced biomarker analysis and AI-enabled data interpretation, but also to evaluate first-line combination therapy with pembrolizumab in NSCLC. Upon completion of the planned Nasdaq uplisting and financing of the study, LDOS007 will become Helix's primary development priority and the catalyst for the next phase of value creation.



### LEUMUNA™ Option Extension with MetaShape Pharma:

On February 5, 2026, we announced the extension of a Research and Exclusive Option Agreement with metaShape Pharma AG covering LEUMUNA through December 31, 2028. Under the agreement, metaShape holds an exclusive research license and option to negotiate a commercial license for LEUMUNA in the field of adipose tissue-related and metabolic diseases. The compound is being developed by metaShape as MS 001, an orally administered, first-in-class co-therapy for GLP-1 receptor agonists, such as semaglutide, aimed at improving fat-selective, muscle-preserving, durable weight loss. For Helix, this extension preserves long-term optionality in high-value metabolic indications as the Company continues to advance its focus on unlocking the potential of its oncology assets in hard-to-treat cancers.

## Traction



AGM 2026: All motions passed with over 99% shareholder approval, reinforcing strong alignment around Helix's strategic direction.

On September 23, 2025, Jonathan Davis, PhD, Director of ADC Discovery at Helix presented its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th World ADC London Conference, held in London, United Kingdom. Dr. Davis' presentation was selected to be presented as part of the conference's opening Seminar Day program, generating strong interest and discussion among conference participants and reflecting the growing recognition of CEACAM6 as an important emerging target in oncology. A copy of Dr. Davis' presentation is available on the Company's website, [here](#).

## From Our Blog

Over the past few months, our blog has covered a broad range of topics in oncology and biomedical science. Here's a quick look at what we've been writing about.

### Obesity, Cancer Risk & the GLP-1 Conversation: What Science Is Really Saying

Excess body fat is metabolically active, creating chronic inflammation, insulin resistance. [Read more](#)

### How Our Understanding of CEACAM6 Has Evolved in the Last 12 Months

CEACAM6 is increasingly recognized as an active driver of tumor growth, immune suppression. [Read more](#)

### Missing the Marker: Clinical Consequences of Incomplete Biomarker Testing

In non-small cell lung cancer, the gap between guideline recommendations... [Read more](#)

### From Gut to Growth Signals: How Obesity Creates a Pro-Cancer Environment

Adipose tissue produces hormones, immune signals, and growth factors that, in obesity [Read more](#)

### An Open Dialogue: What COVID Vaccines, Ozempic, and Aspirin Can Teach Us About Innovation in Oncology

Some of oncology's most significant advances haven't necessarily come from brand [Read more](#)

### If Aging Can Be Reversed, What Does That Mean for Oncology?

Aging is the single greatest risk factor for cancer, and the biological processes [Read more](#)

